Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

December 12, 2023

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

November 07, 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

News Conference News HFSA 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

October 18, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

Chaos and Questions: New Public-Access Policies Put Journals in Flux

News Features

Chaos and Questions: New Public-Access Policies Put Journals in Flux

Michael O'Riordan

August 14, 2023

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

News Daily News

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Michael O'Riordan

July 12, 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

News Conference News EAS 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Michael O'Riordan

May 29, 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

News Conference News EAS 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Michael O'Riordan

May 24, 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

March 14, 2023

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

News Conference News ACC 2023

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

Michael O'Riordan

March 10, 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy

News Daily News

UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy

Michael O'Riordan

January 20, 2023

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.